- Home
- HBB vs ENGN Comparison
HBB vs ENGN Comparison
Compare HBB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- ENGN
- Stock Information
- Founded
- HBB 1904
- ENGN 1999
- Country
- HBB United States
- ENGN Canada
- Employees
- HBB N/A
- ENGN N/A
- Industry
- HBB Home Furnishings
- ENGN
- Sector
- HBB Consumer Discretionary
- ENGN
- Exchange
- HBB Nasdaq
- ENGN Nasdaq
- Market Cap
- HBB 242.8M
- ENGN 321.5M
- IPO Year
- HBB 2017
- ENGN N/A
- Fundamental
- Price
- HBB $14.71
- ENGN $6.52
- Analyst Decision
- HBB
- ENGN Buy
- Analyst Count
- HBB 0
- ENGN 8
- Target Price
- HBB N/A
- ENGN $21.50
- AVG Volume (30 Days)
- HBB 23.7K
- ENGN 225.5K
- Earning Date
- HBB 10-29-2025
- ENGN 09-11-2025
- Dividend Yield
- HBB 3.20%
- ENGN N/A
- EPS Growth
- HBB N/A
- ENGN N/A
- EPS
- HBB 2.35
- ENGN N/A
- Revenue
- HBB $631,318,000.00
- ENGN N/A
- Revenue This Year
- HBB N/A
- ENGN N/A
- Revenue Next Year
- HBB N/A
- ENGN N/A
- P/E Ratio
- HBB $6.22
- ENGN N/A
- Revenue Growth
- HBB N/A
- ENGN N/A
- 52 Week Low
- HBB $12.72
- ENGN $2.65
- 52 Week High
- HBB $31.78
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- HBB 49.22
- ENGN 77.94
- Support Level
- HBB $14.46
- ENGN $5.52
- Resistance Level
- HBB $15.01
- ENGN $6.54
- Average True Range (ATR)
- HBB 0.50
- ENGN 0.55
- MACD
- HBB 0.09
- ENGN 0.11
- Stochastic Oscillator
- HBB 45.41
- ENGN 99.17
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.